Ginkgo Bioworks reports third quarter revenue of $39 million

Reuters

2025/11/07

<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> reports third quarter revenue of $39 million

Ginkgo Bioworks Holdings Inc. reported total revenue of $39.0 million for the third quarter of 2025, down 56% from $89.0 million in the same period of the previous year. The prior year's revenue included $45.0 million in non-cash revenue from a release of deferred revenue due to the mutual termination of a customer agreement. Excluding this impact, third quarter 2025 revenue decreased by 11% compared to the previous year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $462.0 million. Ginkgo continues to expect at least $40.0 million in Biosecurity revenue for 2025. Recent business developments include new partnerships leveraging AI-enabled cloud lab technology, with ongoing deals in agriculture and with the U.S. government.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18014) on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581010161"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581010161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581010161?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581010161","market":"us","top_or_hot":-1,"title":"Ginkgo Bioworks reports third quarter revenue of $39 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> reports third quarter revenue of $39 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> reported total revenue of $39.0 million for the third quarter of 2025, down 56% from $89.0 million in the same period of the previous year. The prior year's revenue included $45.0 million in non-cash revenue from a release of deferred revenue due to the mutual termination of a customer agreement. Excluding this impact, third quarter 2025 revenue decreased by 11% compared to the previous year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $462.0 million. Ginkgo continues to expect at least $40.0 million in Biosecurity revenue for 2025. Recent business developments include new partnerships leveraging AI-enabled cloud lab technology, with ongoing deals in agriculture and with the U.S. government.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18014) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks reports third quarter revenue of $39 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks reports third quarter revenue of $39 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> reports third quarter revenue of $39 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> reported total revenue of $39.0 million for the third quarter of 2025, down 56% from $89.0 million in the same period of the previous year. The prior year's revenue included $45.0 million in non-cash revenue from a release of deferred revenue due to the mutual termination of a customer agreement. Excluding this impact, third quarter 2025 revenue decreased by 11% compared to the previous year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $462.0 million. Ginkgo continues to expect at least $40.0 million in Biosecurity revenue for 2025. Recent business developments include new partnerships leveraging AI-enabled cloud lab technology, with ongoing deals in agriculture and with the U.S. government.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18014) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNA","symbol_name":"Ginkgo Bioworks Holdings Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1dzHlS:1","article_id":"2581010161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581010161","pubTimestamp":1762463536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ginkgo Bioworks Holdings Inc. reported total revenue of $39.0 million for the third quarter of 2025, down 56% from $89.0 million in the same period of the previous year. The prior year's revenue included $45.0 million in non-cash revenue from a release of deferred revenue due to the mutual termination of a customer agreement. Excluding this impact, third quarter 2025 revenue decreased by 11% compared to the previous year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $462.0 million. Ginkgo continues to expect at least $40.0 million in Biosecurity revenue for 2025. Recent business developments include new partnerships leveraging AI-enabled cloud lab technology, with ongoing deals in agriculture and with the U.S. government.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNA":"Ginkgo Bioworks Holdings Inc.","BK4139":"生物科技","BK4109":"特种化学制品","BK4121":"生命科学工具和服务"},"translate_title":"Ginkgo Bioworks报告第三季度营收为3900万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA":0.9},"content_text":"Ginkgo Bioworks reports third quarter revenue of $39 million\n    \n\nGinkgo Bioworks Holdings Inc. reported total revenue of $39.0 million for the third quarter of 2025, down 56% from $89.0 million in the same period of the previous year. The prior year's revenue included $45.0 million in non-cash revenue from a release of deferred revenue due to the mutual termination of a customer agreement. Excluding this impact, third quarter 2025 revenue decreased by 11% compared to the previous year. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $462.0 million. Ginkgo continues to expect at least $40.0 million in Biosecurity revenue for 2025. Recent business developments include new partnerships leveraging AI-enabled cloud lab technology, with ongoing deals in agriculture and with the U.S. government.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE18014) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}